• Phone+442871675274
  • Cromore Road, Coleraine Campus

    BT52 1SA Coleraine

    United Kingdom

  • 107 Citations
  • 5 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Kyle Matchett completed his PhD in October 2010 at Queen’s University Belfast (QUB). His thesis examined the expression of SEPT9 splice variants in ovarian tumours from the SCOTROC trial and array CGH studies with the Institute of Cancer Research, London.

Following his PhD, Dr Matchett was appointed as a Cancer Research UK Postdoctoral Research Fellow at QUB. He discovered that estrogen metabolism is deregulated in BRCA1-deficient breast cells leading to increased production of estrogen metabolites and metabolite-induced DNA damage. Dr Matchett published his work in Cancer Research, and presented it at conferences in Montreal, London and Amsterdam. In recognition of this research, Dr Matchett was awarded the inaugural Professor John Fitzpatrick Prize by the Irish Association for Cancer Research (IACR).

Dr Matchett continued his interest in hormone signalling in breast cancer and moved to take up an EU FP7 Postdoctoral Research Fellow position focused on understanding the role of erythropoietin (EPO) in breast cancer. Based at QUB, his post involved collaboration and extensive travel with partner laboratories in Madrid, Innsbruck, Tel-Aviv, Vienna, Munich and Zurich. During this time, Dr Matchett played a key role in the development of novel EPO receptor antibodies with industrial partners Aldevron (Germany). He also led his own research which resulted in several publications.

In 2015, Dr Matchett was appointed as a Leukaemia and Leukaemia NI Postdoctoral Research Fellow following an increasing interest in haematology. His research focused on developing novel therapeutics for paediatric and adult acute myeloid leukaemia. This work has been recognised both nationally and internationally with a number of grants, invited talks and awards, including a presentation prize at XXXVI World Congress of the International Society of Haematology (2016), Little Princess Trust/Childhood Cancer and Leukaemia Group Project Grant Awards (2017, 2018) and a Novartis Fellowship Prize and Medal (2017).

In addition to his research programme, Dr Matchett completed his PGCHET in 2014 and was awarded a Fellowship of the Higher Education in 2015. He co-led a School-wide study examining postgraduate research student support, which was published in 2018.

Dr Matchett was appointed as a Lecturer at Ulster University in October 2018.

Fingerprint Dive into the research topics where Kyle Matchett is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 18 Similar Profiles
Neoplasms Medicine & Life Sciences
Erythropoietin Receptors Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Erythropoietin Medicine & Life Sciences
HSP90 Heat-Shock Proteins Medicine & Life Sciences
ras Proteins Medicine & Life Sciences
Photosensitizing Agents Medicine & Life Sciences
Genomic Instability Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2014 2019

  • 107 Citations
  • 5 h-Index
  • 8 Article
5 Citations (Scopus)

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

haggag, Y., Matchett, K., Falconer, R. A., Isreb, M., Jones, J., Faheem, A., McCarron, P. A. & El Tanani, M., 14 Feb 2019, In : Cancers. 11, 2, 222.

Research output: Contribution to journalArticle

Open Access
ras Proteins
Chromosomes, Human, Pair 1
2 Citations (Scopus)

Intradermal Delivery of a Near-Infrared Photosensitizer Using Dissolving Microneedle Arrays

Hamdan, I. M. N., Tekko, I. A., Matchett, K. B., Arnaut, L. G., Silva, C. S., McCarthy, H. O. & Donnelly, R. F., 1 Sep 2018, In : Journal of Pharmaceutical Sciences. 107, 9, p. 2439-2450 12 p.

Research output: Contribution to journalArticle

Photosensitizing Agents
Nude Mice
5 Citations (Scopus)

Erythropoietin drives breast cancer progression by activation of its receptor EPOR

Chan, K-K., Matchett, K. B., Coulter, J. A., Yuen, H-F., McCrudden, C. M., Zhang, S-D., Irwin, G. W., Davidson, M. A., Rülicke, T., Schober, S., Hengst, L., Jaekel, H., Platt-Higgins, A., Rudland, P. S., Mills, K. I., Maxwell, P., El-Tanani, M. & Lappin, T. R., 18 Mar 2017, In : Oncotarget. 8, 24, p. 38251-38263 13 p.

Research output: Contribution to journalArticle

Open Access
Breast Neoplasms
Erythropoietin Receptors
Phosphatidylinositol 3-Kinases
6 Citations (Scopus)

Low-dose salinomycin induces anti-leukemic responses in AML and MLL

Roulston, G. DR., Burt, C. L., Kettyle, L. MJ., Matchett, K. B., Keenan, H. L., Mulgrew, N. M., Ramsey, J. M., Dougan, C., McKiernan, J., Grishagin, I. V., Mills, K. I. & Thompson, A., 1 Sep 2016, In : Oncotarget. 7, 45, p. 73448-73461 14 p.

Research output: Contribution to journalArticle

Open Access
Computational Biology
7 Citations (Scopus)

Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling

Yuen, H-F., Chan, K-K., Platt-Higgins, A., Dakir, E-H., Matchett, K. B., Haggag, Y. A., Jithesh, P. V., Habib, T., Faheem, A., Fennell, D. A., Morgan, R., Rudland, P. S. & El-Tanani, M., 15 Nov 2016, In : Oncotarget. 7, 46, p. 75854–75864 11 p.

Research output: Contribution to journalArticle

Open Access
GTP Phosphohydrolases
Breast Neoplasms
Cell Line
Matrix Metalloproteinases
Cell Adhesion